ETONEton Pharmaceuticals, Inc.
$54.73+159% 1Y
$54.73
$14.3552 weeks$64.38
The financials
Eton Pharmaceuticals, Inc. by the numbers
Eton Pharmaceuticals, Inc. (ETON) reported revenue of $38M in Q2 2026 (quarter ended Jun 30, 2026), up 99% from the same quarter a year earlier. That came with a gross margin of 68% and net income of $12M (31% of revenue). For the full year FY2025, revenue was $80M (+105% year on year) and net income −$4.6M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $38M | $19M | +99% |
| Gross profit | $25M | $12M | +113% |
| Operating income | $13M | −$1.5M | to a profit |
| Net income | $12M | −$2.6M | to a profit |
| Diluted EPS | $0.35 | −$0.10 | to a profit |
Drug Manufacturers, Specialty & Generic
Ranks #34 of 41 by RyuScore